

May  
11-12  
2017

# TRAINING COURSE



## « Orphan drug and rare disease - Accelerating access to therapeutic innovation » 4<sup>th</sup> edition

On the 11<sup>th</sup> and 12<sup>th</sup> of May 2017, the EUDIPHARM Claude Bernard University, the F-CRIN labeled service platform Orphandev and the Training & Education Unit of F-CRIN's Coordination are co-organizing the 4th edition of the "Orphan drug & rare disease - Accelerating access to therapeutic innovation " training course. While the methodology remains the main focus of the program, this year will also be the opportunity to address more specifically the EMA tools in drug development but also the issues around personalized medicine.

### Who ?

This training course is aimed at clinical research professionals, project promoters but also patient associations, involved in rare diseases and in the development of orphan drugs.

### Why ?

This training seminar aims at raising awareness among clinical research actors on drug development specificities for rare diseases:

- **Identify** tools for drug development
- **Consolidate** practices
- **Apprehend** the stakes

### How ?

Participants will discuss and deepen the topics proposed through:

- Knowledge capitalization
- Feedbacks
- Projection of practices
- Interactions and exchanges with clinical research actors

### Highlights

- + Participatory teaching methods
- Intervention of experts in the field
- Approach to tools and methodology
- Participation of the leading players of the clinical research

### Training stakeholders

#### Speakers

European Medicines Agency  
ANSM  
Academic experts  
Experts from the private sector  
Patient associations  
[...]

#### Organisation committee

**Eudipharm** : Behrouz Kassaï & Catherine Cornu  
**Orphandev** : Olivier Blin & Cécile Colomban  
**F-CRIN** : Vincent Diebolt & Allan Wilsdorf

#### Partners



**Date:** 11th and 12th May 2017

**Location :** Marseille – Hôpital La Timone

**Training course in english**

**Online registration:** [link](#)

**Contact:** [leila.bachir@inserm.fr](mailto:leila.bachir@inserm.fr)

May  
11-12  
2017

# PROGRAMME



« Orphan drug and rare disease - Accelerating access to therapeutic innovation » 4<sup>th</sup> edition

**Day 1 – Thursday 11th May 2017**

## Opening - 13:30

- **Welcome coffee**
- **Opening statement**



Pr Behrouz Kassāi, Lyon University Hospital

## Drug development : the EMA tools

- **Orphan designation and protocol assistance: incentives for the development of therapies for rare diseases**

Annie Lorence, ANSM (Agence Nationale de Sécurité du médicament et des produits de santé - National agency for drugs and health products safety), member of the Committee for Orphan Medicinal Products (COMP) at the EMA (European Medicines Agency)

- **Academic experience of therapeutic development: Stromal Vascular Fraction of Adipose tissue for Scleroderma Therapy**

Dr Jérémy Magalon, Cell Culture and Therapy Laboratory, Conception Hospital, AP-HM (Marseille University Hospitals)

## Discussions



- **Paediatric Investigation Plan**

Sylvie Benchetrit, ANSM (Agence Nationale de Sécurité du médicament et des produits de santé - National agency for drugs and health products safety)

- **Feedback experience : development of Macitentan for the treatment of pulmonary arterial hypertension in children**

Catherine Lesage, Senior Director, Clinical Science Pediatrics Program Head, Actelion

## Discussions

## Newsflash - PedCRIN: Capacity building project for multinational paediatric clinical trials

Salma Malik, PedCRIN

## End of day 1 - 17:30

May  
11-12  
2017

# PROGRAMME



« Orphan drug and rare disease - Accelerating access to therapeutic innovation » 4<sup>th</sup> edition

**Day 2 – Friday 12th May 2017**

## Opening - 08:30

- **Welcome coffee** 

## Newsflash - Health research priorities setting

Pr Behrouz Kassai, Lyon University Hospital

## Methodology

- **Presentation and feedback: example of a size-1 trial and its meta-analysis in Wilson's disease**

Pr Stéphane Thobois and Pr Behrouz Kassai, Lyon University Hospital



## Drug repositioning

- **Drug repositioning: new indications for old drugs**  
Olivier Blin, Head of Clinical Pharmacology Department, Timone Hospital, AP-HM (Marseille University Hospitals), OrphanDev coordinator
- **Feedback: Repositioning of Rimeporide in Duchene muscular dystrophy**  
Florence Porte Thomé, R&D Director, EspeRare Foundation

## Personalised medicine [1/2]

- **Participative workshop [1/2]**  
Leïla Bachir, F-CRIN

**12:30 – Lunch break – 13h30**

## Personalised medicine [2/2]

- **Personalized medicine for cystic fibrosis**  
Dr François Vermeulen, Catholic University of Leuven
- **Drug development in progeria**  
Pr Nicolas Levy, Head of medical genetics department, Timone Hospital, AP-HM (Marseille University Hospitals)
- **Participative workshop [2/2]**  
Leïla Bachir, F-CRIN
- **Table ronde**  
Academic and industry professionals as well as patients, expert children and national authorities' representatives

**End of day 2 - 15:30**

May  
11-12  
2017

# INFORMATION



« Orphan drug and rare disease - Accelerating access to therapeutic innovation » 4<sup>th</sup> edition

## Online registrations

F-CRIN infrastructure's website : [registration form](#)

## Fees

### Academic/institution

first registration for a structure: 300€ (Day2 only) / 450€ (Day1+Day2)  
additional registration for the same structure: 250€ (Day2 only) / 400€ (Day1+Day2)

### Student

Single price : 50€ (Day2 only) / 80€ (Day1+Day2)

Coffee breaks & lunches are included.

### Industry

first registration for a structure: 450€ (Day2 only) / 650€ (J1+J2)  
additional registration for the same structure: 400€ (Day2 only) / 600€ (Day1+Day2)

### Patient associations

Single price : 50€ (Day2 only) / 80€ (Day1+Day2)

## Site access



### Address

Amphithéâtre HA2  
Hôpital La Timone  
264 Rue Saint-Pierre - 13005 Marseille

### GPS coordinates

43.291712, 5.402719

### Phone contact

Your contact on site  
Leïla Bachir  
05 34 55 75 87

### Underground

Line 1, station Timone